

CALIFORNIA STI TREATMENT GUIDELINES TABLE FOR ADULTS & ADOLESCENTS

These guidelines reflect the 2021 CDC STI Treatment Guidelines for adults and adolescents who are HIV negative as well as those with HIV. Call the local health department for assistance with confidential notification of sexual partners of patients with STIs or HIV. For complex STI clinical management consultation (such as in cases of multiple allergies or treatment failure), contact the California Department of Public Health STD Control Branch via email (stdcb@cdph.ca.gov) or phone (510-620-3400) or submit your question online to the STD Clinical Consultation Network at www.stdccn.org. An ADA-compliant version of this document is posted online at <https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/California-STI-Treatment-Guidelines.aspx>.

INFECTION/DISEASE	RECOMMENDED REGIMENS	ALTERNATIVE REGIMENS: To be used if medical contraindication to recommended regimen.
CHLAMYDIA (CT)		
Urogenital/Rectal/Pharyngeal Infections	<ul style="list-style-type: none"> • Doxycycline¹ 100 mg po bid x 7 d 	<ul style="list-style-type: none"> • Azithromycin 1 g po x 1 dose OR • Levofloxacin 500 mg po once daily x 7 d
Pregnant Patients ²	<ul style="list-style-type: none"> • Azithromycin 1 g po x 1 dose 	<ul style="list-style-type: none"> • Amoxicillin 500 mg po tid x 7 d
GONORRHEA (GC): Monotherapy with IM ceftriaxone is recommended for all patients with gonorrhea, including pregnant patients. If co-infection with chlamydia has not been excluded, add doxycycline 100 mg po bid x 7 d for non-pregnant persons or azithromycin 1 g po x 1 dose for pregnant persons.		
Urogenital/Rectal Infections ³	<ul style="list-style-type: none"> • Ceftriaxone 500 mg IM x 1 dose for persons weighing <150 kg⁴ OR • Ceftriaxone 1 g IM x 1 dose for persons weighing ≥150 kg 	<p>If cephalosporin allergy: dual therapy with</p> <ul style="list-style-type: none"> • Gentamicin¹ 240 mg IM x 1 dose PLUS • Azithromycin 2 g po x 1 dose <p>If ceftriaxone not available or feasible, but no allergy concerns:</p> <ul style="list-style-type: none"> • Cefixime 800 mg x 1 dose⁵
Pharyngeal Infections ^{3,6}	<ul style="list-style-type: none"> • Ceftriaxone 500 mg IM x 1 dose for persons weighing <150 kg⁴ OR • Ceftriaxone 1 g IM x 1 dose for persons weighing ≥150 kg 	No reliable treatment alternatives. Consult an infectious disease specialist or submit a question online at www.stdccn.org .
PELVIC INFLAMMATORY DISEASE (PID)⁷ (Etiologies: CT, GC, anaerobes, possibly <i>M. genitalium</i> , others)	<p>Parenteral</p> <ul style="list-style-type: none"> • Ceftriaxone 1 g IV q 24 hrs PLUS • Doxycycline¹ 100 mg IV or po q 12 hrs PLUS • Metronidazole 500 mg IV or po q 12 hrs OR • Either Cefotetan 2 g IV q 12 h OR Cefoxitin 2 g IV q 6 h PLUS • Doxycycline¹ 100 mg po or IV q 12 hrs <p>IM/Oral</p> <ul style="list-style-type: none"> • Either Ceftriaxone 500 mg IM x 1 dose⁴ (or another 3rd generation cephalosporin⁸) OR • Cefoxitin 2 g IM x 1 dose administered with Probenecid 1 g po x 1 dose PLUS • Doxycycline¹ 100 mg po bid x 14 d WITH • Metronidazole 500 mg po bid x 14 d 	<p>Parenteral</p> <ul style="list-style-type: none"> • Ampicillin/Sulbactam 3 g IV q 6 hrs PLUS • Doxycycline¹ 100 mg po or IV q 12 hrs OR • Clindamycin 900 mg IV q 8 hrs PLUS • Gentamicin¹ 2 mg/kg IV or IM x 1 as loading dose FOLLOWED BY • Gentamicin¹ 1.5 mg/kg IV or IM q 8 h as maintenance dose (or can substitute with Gentamicin¹ 3-5 mg/kg IM or IV 1x daily) <p>IM/Oral⁹</p> <ul style="list-style-type: none"> • Either Levofloxacin 500 mg po daily OR Moxifloxacin 400 mg po daily, WITH Metronidazole 500 mg po bid x 14 d OR • Azithromycin 500 mg IV daily x 1-2 doses followed by 250 mg po daily WITH Metronidazole 500 mg po bid x 12-14 d
CERVICITIS¹⁰ (Etiologies: CT, GC, <i>T. vaginalis</i> , HSV, possibly <i>M. genitalium</i>)	<ul style="list-style-type: none"> • Doxycycline¹ 100 mg po bid x 7 d 	<ul style="list-style-type: none"> • Azithromycin 1 g po x 1 dose
NONGONOCOCCAL URETHRITIS (NGU)¹⁰	<ul style="list-style-type: none"> • Doxycycline¹ 100 mg po bid x 7 d 	<ul style="list-style-type: none"> • Azithromycin 1 g po x 1 dose OR • Azithromycin 500 mg po x 1 dose, then 250 mg po daily x 4 d
RECURRENT/PERSISTENT NGU (Etiologies: <i>M. genitalium</i> (MG), <i>T. vaginalis</i> , other bacteria)	<p>1) Test for <i>M. genitalium</i> (MG)</p> <p>If MG test positive but resistance testing unavailable, use:</p> <ul style="list-style-type: none"> • Doxycycline¹ 100 mg po bid x 7 d FOLLOWED BY • Moxifloxacin 400 mg po daily x 7 d <p>If MG test positive and resistance testing is available, use:</p> <p>Macrolide sensitive:</p> <ul style="list-style-type: none"> • Doxycycline¹ 100 mg po bid x 7 d FOLLOWED BY • Azithromycin 1 g po once, then 500 mg daily on next 3 d <p>Macrolide resistant:</p> <ul style="list-style-type: none"> • Doxycycline¹ 100 mg po bid x 7 d FOLLOWED BY • Moxifloxacin 400 mg po daily x 7 d <p>2) Test and treat presumptively for <i>T. vaginalis</i> in men who have sex with women (MSW) in areas where infection is prevalent</p> <ul style="list-style-type: none"> • Metronidazole or Tinidazole 2 g po x 1 dose (applies to both medications) 	<p>For settings without MG resistance testing and when moxifloxacin cannot be used:</p> <ul style="list-style-type: none"> • Doxycycline¹ 100 mg po bid x 7 d PLUS • Azithromycin 1 g po x 1 dose on first day FOLLOWED BY • Azithromycin 500 mg po once daily for 3 d AND • Perform a test of cure 21 d after treatment
PROCTITIS: (Etiologies: GC, CT including LGV, HSV, <i>T. pallidum</i> , possibly <i>M. genitalium</i>);	<ul style="list-style-type: none"> • Ceftriaxone 500 mg IM x 1 dose for persons weighing <150 kg⁴ OR • Ceftriaxone 1 g IM x 1 dose for persons weighing ≥150 kg PLUS • Doxycycline¹ 100 mg po bid x 7 d¹¹ 	<ul style="list-style-type: none"> • None
LYMPHOGRANULOMA VENEREUM (LGV)	<ul style="list-style-type: none"> • Doxycycline¹ 100 mg po bid x 21 d 	<ul style="list-style-type: none"> • Azithromycin 1 g po once weekly x 3 weeks¹² OR • Erythromycin base 500 mg po qid x 21 d
TRICHOMONIASIS¹³ NOTE: Treatment recommendations do not vary by HIV status.		
Cervicovaginal infection	<ul style="list-style-type: none"> • Metronidazole 500 mg po bid x 7 d 	<ul style="list-style-type: none"> • Tinidazole¹⁴ 2 g po x 1 dose OR • Secnidazole¹⁵ 2 g po x 1 dose
Penile infection	<ul style="list-style-type: none"> • Metronidazole 2 g po x 1 dose 	

¹ Contraindicated for pregnant patients.

² Every effort should be made to use a recommended regimen. Test-of-cure follow-up with a nucleic acid amplification test (NAAT) 4 weeks after completion of therapy is recommended in pregnancy.

³ See Gonorrhea Treatment Guidelines and Management of Suspected Treatment Failure (https://www.cdph.ca.gov/Programs/CID/DCDC/CDPH%20Document%20Library/CAGCTreatmentFailureProtocol_Providers.pdf) if suspected GC treatment failure.

⁴ For persons weighing ≥150 kg, use 1 gm IM ceftriaxone x 1 dose instead.

⁵ Oral cephalosporins give lower and less-sustained bactericidal levels than ceftriaxone. Cefixime should only be used when ceftriaxone is not available.

⁶ Test of cure by culture or NAAT is recommended 14 days after treatment of pharyngeal GC.

⁷ If parenteral therapy is selected initially, discontinue 24-48 hours after patient improves clinically and continue with either IM or oral therapy for a total of 14 days.

⁸ Other parenteral third-generation cephalosporin (e.g. cefotaxime or ceftizoxime) could be substituted for ceftriaxone.

⁹ If allergy to cephalosporins, can consider fluoroquinolones/azithromycin for PID treatment if community prevalence and individual risk of GC is low, and follow-up is assured. Obtain NAAT testing and GC culture before using fluoroquinolone/azithromycin treatment.

¹⁰ If patient lives in community with high GC prevalence, or has risk factors (e.g. age <25 years, new partner, partner with concurrent sex partners, or sex partner with a STI), consider empiric treatment for GC.

¹¹ Extend doxycycline course to 21 days to cover LGV if perianal or mucosal ulcers, bloody rectal discharge, or tenesmus and rectal CT positive. If perianal or mucosal ulcers present, consider treating for HSV as well.

¹² Because this regimen has not been rigorously validated, consider a test of cure with CT NAAT four weeks after treatment.

¹³ For suspected drug-resistant trichomoniasis consult the 2021 CDC STI treatment guidelines, contact the CA STD Control Branch, or consult www.stdccn.org.

¹⁴ Safety in pregnancy has not been established, avoid during pregnancy. When using tinidazole, breastfeeding should be deferred for 72 hours after 2 g dose.

¹⁵ Sprinkle oral granules on applesauce/yogurt/pudding before ingestion. Glass of water after dose can aid in swallowing. FDA-approved for treatment of trichomonas after the release of the CDC's 2021 STI Treatment Guidelines.

INFECTION/DISEASE	RECOMMENDED REGIMENS	ALTERNATIVE REGIMENS: To be used if medical contraindication to recommended regimen.
BACTERIAL VAGINOSIS	<ul style="list-style-type: none"> Metronidazole 500 mg po bid x 7 d OR Metronidazole gel 0.75% one full applicator (5 g) intravaginally once daily x 5 d OR Clindamycin cream 2% one full applicator (5 g) intravaginally qhs x 7 d 	<ul style="list-style-type: none"> Tinidazole¹⁴ 2 g po daily x 2 d OR Tinidazole¹⁴ 1 g po daily x 5 d OR Secnidazole¹⁵ 2 g po x 1 dose OR Clindamycin 300 mg po bid x 7 d OR Clindamycin ovules¹⁶ 100mg intravaginally qhs x 3 d
EPIDIDYMITIS	<p>If likely due to GC or CT</p> <ul style="list-style-type: none"> Ceftriaxone 500 mg IM x 1 dose⁴ PLUS Doxycycline 100 mg po bid x 10 d <p>If likely due to GC, CT or enteric organisms (history of insertive anal sex)</p> <ul style="list-style-type: none"> Ceftriaxone 500 mg IM x 1 dose⁴ PLUS Levofloxacin 500 mg po daily x 10 d <p>If most likely due to enteric organisms alone (GC and CT tests negative)</p> <ul style="list-style-type: none"> Levofloxacin¹⁷ 500 mg po daily x 10 d 	<ul style="list-style-type: none"> None
ANOGENITAL WARTS		
External Genital/Perianal Warts	<p>Patient-Applied</p> <ul style="list-style-type: none"> Imiquimod^{18,19} 5% cream topically qhs 3x/wk up to 16 wks OR Imiquimod^{18,19} 3.75% cream topically qhs for up to 8 wks OR Podofilox 0.5% solution or gel topically bid x 3 d then 4 d off, repeat up to 4 cycles OR Sinecatechins¹⁸ 15% ointment topically tid for up to 16 wks <p>Provider-Administered</p> <ul style="list-style-type: none"> Cryotherapy with liquid nitrogen, apply once q1-2 wks OR Trichloroacetic acid (TCA) 80%-90%, apply once q 1-2 wks OR Bichloroacetic acid (BCA) 80%-90%, apply once q 1-2 wks OR Surgical removal 	<p>Alternative Regimen – (fewer data available)</p> <p>Provider Administered</p> <ul style="list-style-type: none"> Podophyllin resin²⁰ 10-25% in tincture of benzoin, applied weekly PRN OR Intralesional interferon OR Photodynamic therapy OR Topical cidofovir
Mucosal Genital Warts	<p>Urethral meatus, Vaginal, Cervical, Intra-Anal</p> <ul style="list-style-type: none"> Cryotherapy²¹ with liquid nitrogen OR Surgical removal OR <p>Vaginal, Cervical, Intra-anal</p> <ul style="list-style-type: none"> TCA or BCA 80-90% 	<ul style="list-style-type: none"> None
ANOGENITAL HERPES		
First Clinical Episode of Herpes ²²	<ul style="list-style-type: none"> Acyclovir 400 mg po tid x 7-10 d OR Valacyclovir 1 g po bid x 7-10 d OR Famciclovir 250 mg po tid x 7-10 d 	<ul style="list-style-type: none"> None
Daily Suppressive Therapy for Recurrences (if no HIV co-infection)	<ul style="list-style-type: none"> Acyclovir 400 mg po bid OR Valacyclovir 500 mg po daily²³ OR Valacyclovir 1 g po daily OR Famciclovir²⁴ 250 mg po bid 	<ul style="list-style-type: none"> None
Daily Suppressive Therapy in Pregnant Patients (start at 36 weeks gestation)	<ul style="list-style-type: none"> Acyclovir 400 mg po tid OR Valacyclovir 500 mg po bid 	
Episodic Therapy for Recurrences (If no HIV co-infection)	<ul style="list-style-type: none"> Acyclovir 800 mg po bid x 5 d OR Acyclovir 800 mg po tid x 2 d OR Valacyclovir 500 mg po bid x 3 d OR Valacyclovir 1 g po daily x 5 d OR Famciclovir 1 gm po bid x 1 d OR Famciclovir 500 mg po once, then 250 mg po bid x 2 d OR Famciclovir 125 mg po bid x 5 d 	
Persons with HIV²⁵		
Daily Suppressive Therapy	<ul style="list-style-type: none"> Acyclovir 400-800 mg po 2-3 times daily OR Valacyclovir 500 mg po bid OR Famciclovir²⁴ 500 mg po bid 	<ul style="list-style-type: none"> None
Episodic Therapy for Recurrences	<ul style="list-style-type: none"> Acyclovir 400 mg po tid x 5-10 d OR Valacyclovir 1 gm po bid x 5-10 d OR Famciclovir 500 mg po bid x 5-10 d 	
SYPHILIS²⁶ NOTE: Treatment recommendations do not vary by HIV status.		
Primary, Secondary, and Early Latent	<ul style="list-style-type: none"> Benzathine penicillin G 2.4 million units IM x 1 dose 	<ul style="list-style-type: none"> Doxycycline²⁷ 100 mg po bid x 14 d OR Tetracycline²⁷ 500 mg po qid x 14 d OR Ceftriaxone²⁷ 1 g IM or IV daily x 10-14 d
Late Latent or Syphilis of Unknown Duration OR Tertiary Syphilis with normal CSF	<ul style="list-style-type: none"> Benzathine penicillin G 7.2 million units total, administered as 3 doses of 2.4 million units IM each at 1 week intervals²⁸ 	<ul style="list-style-type: none"> Doxycycline²⁷ 100 mg po bid x 28 d OR Tetracycline²⁷ 500 mg po qid x 28 d
Neurosyphilis and Ocular Syphilis ²⁹	<ul style="list-style-type: none"> Aqueous crystalline penicillin G 18-24 million units daily, administered as 3-4 million units IV q 4 hrs or as continuous infusion x 10-14 d 	<ul style="list-style-type: none"> Procaine penicillin G 2.4 million units IM daily x 10-14 d PLUS Probenecid 500 mg po qid x 10-14 d OR, in the setting of severe penicillin allergy Ceftriaxone²⁷ 1-2 gm IM or IV daily x 10-14 d
Pregnant Patients³⁰ NOTE: Pregnant patients who miss any dose of therapy must repeat full course of treatment.		
Primary, Secondary, and Early Latent	<ul style="list-style-type: none"> Benzathine penicillin G 2.4 million units IM x 1 dose³¹ 	<ul style="list-style-type: none"> None
Late Latent or Syphilis of Unknown Duration OR Tertiary Syphilis with normal CSF	<ul style="list-style-type: none"> Benzathine penicillin G 7.2 million units total, administered as 3 doses of 2.4 million units IM each, at 1-week intervals³² 	<ul style="list-style-type: none"> None
Neurosyphilis and Ocular Syphilis ²⁹	<ul style="list-style-type: none"> Aqueous crystalline penicillin G 18-24 million units daily, administered as 3-4 million units IV q 4 hrs or as continuous infusion x 10-14 d 	<ul style="list-style-type: none"> Procaine penicillin G 2.4 million units IM daily x 10-14 d PLUS Probenecid 500 mg po qid x 10-14 d

¹⁶ Clindamycin ovules may weaken latex or rubber products (such as condoms and diaphragms). Use of such products within 72 hours following use of clindamycin ovules is not recommended.

¹⁷ Gonorrhea should be ruled out prior to starting a fluoroquinolone-based regimen.

¹⁸ May weaken condoms and vaginal diaphragms. Advise patients to follow package insert directions carefully. Imiquimod users wash area 6-10 hours after application. Sinecatechin ointment should not be washed off.

¹⁹ Limited human data on imiquimod use in pregnancy; animal data suggest low risk.

²⁰ Podophyllin resin is an alternative rather than recommended regimen **due to reports of severe toxicity**. The safety of podophyllin in pregnancy has not been established.

²¹ The use of a cryoprobe in the vagina is not advised due to risk of vaginal perforation and fistula formation.

²² Treatment can be extended if healing is incomplete after 10 days of antiviral therapy.

²³ Consider high dose valacyclovir (1 gm daily) or acyclovir in people who have frequent recurrences (i.e., 10 or more episodes annually).

²⁴ Famciclovir is somewhat less effective for suppression of viral shedding.

²⁵ If concern for resistance based on persistent HSV lesions, obtain a viral isolate for sensitivity testing. Consultation with an infectious disease expert is recommended.

²⁶ Benzathine penicillin G is available in only one long-acting formulation, Bicillin® L-A (the trade name), which contains only benzathine penicillin G. Other combination products, such as Bicillin® C-R, contain both long- and short-acting penicillins and are not effective for treating syphilis.

²⁷ Alternative regimens should be used only for penicillin-allergic patients. If compliance or follow-up cannot be ensured, the patient should be desensitized and treated with benzathine penicillin.

²⁸ In non-pregnant patients, pharmacologic considerations reveal an interval of 7-9 days is ideal.

²⁹ Some specialists recommend 2.4 million units of benzathine penicillin G once weekly for 1 to 3 weeks immediately after completion of neurosyphilis treatment.

³⁰ **Pregnant patients allergic to penicillin should be desensitized and treated with penicillin. There are no alternatives.**

³¹ For early syphilis, many experts give a 2nd dose of benzathine penicillin G 2.4 million units IM one week after the initial dose.

³² **The optimal treatment interval in pregnancy is 7 days. If treatment occurs outside of 6-8-day intervals, the full treatment course should be restarted.**